BRIEF-Tianjin Development Posts FY Results For Tianjin Lisheng Pharmaceutical

Reuters03-25

BRIEF-Tianjin Development Posts FY Results For <a href="https://laohu8.com/S/002393">Tianjin Lisheng</a> Pharmaceutical

March 25 (Reuters) - Tianjin Development 0882.HK:

FY NET PROFIT ATTRIBUTABLE FOR TIANJIN LISHENG PHARMACEUTICAL RMB416.3 MILLION
FY TOTAL OPERATING INCOME FOR TIANJIN LISHENG PHARMACEUTICAL RMB1.39 BILLION

Further company coverage: 002393.SZ

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622601769?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 08:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622601769","market":"us","top_or_hot":-1,"title":"BRIEF-Tianjin Development Posts FY Results For Tianjin Lisheng Pharmaceutical","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Tianjin Development Posts FY Results For <a href=\"https://laohu8.com/S/002393\">Tianjin Lisheng</a> Pharmaceutical </title></head><body><p><span>March 25 (Reuters)</span><span> - </span>Tianjin Development <span>0882.HK</span>:</p><ul><li><p>FY NET PROFIT ATTRIBUTABLE FOR TIANJIN LISHENG PHARMACEUTICAL RMB416.3 MILLION</p></li><li><p>FY TOTAL OPERATING INCOME FOR TIANJIN LISHENG PHARMACEUTICAL RMB1.39 BILLION</p></li></ul><p>Further company coverage: <span>002393.SZ</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Tianjin Development Posts FY Results For Tianjin Lisheng Pharmaceutical</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Tianjin Development Posts FY Results For Tianjin Lisheng Pharmaceutical\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-25 08:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Tianjin Development Posts FY Results For <a href=\"https://laohu8.com/S/002393\">Tianjin Lisheng</a> Pharmaceutical </title></head><body><p><span>March 25 (Reuters)</span><span> - </span>Tianjin Development <span>0882.HK</span>:</p><ul><li><p>FY NET PROFIT ATTRIBUTABLE FOR TIANJIN LISHENG PHARMACEUTICAL RMB416.3 MILLION</p></li><li><p>FY TOTAL OPERATING INCOME FOR TIANJIN LISHENG PHARMACEUTICAL RMB1.39 BILLION</p></li></ul><p>Further company coverage: <span>002393.SZ</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002393","symbol_name":"力生制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40C16D:1","article_id":"2622601769","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622601769","pubTimestamp":1774400170,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Tianjin Development Posts FY Results For Tianjin Lisheng Pharmaceutical March 25  - Tianjin Development 0882.HK:FY NET PROFIT ATTRIBUTABLE FOR TIANJIN LISHENG PHARMACEUTICAL RMB416.3 MILLIONFY TOTAL OPERATING INCOME FOR TIANJIN LISHENG PHARMACEUTICAL RMB1.39 BILLIONFurther company coverage: 002393.SZ ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"002393":"力生制药","BK0239":"医药制造","BK1232":"复合型公用事业","BK0028":"国家队","00882":"天津发展","BK0188":"融资融券"},"translate_title":"简报-天津发展公布天津力生制药财年业绩","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002393":0.9,"00882":0.9},"content_text":"BRIEF-Tianjin Development Posts FY Results For Tianjin Lisheng Pharmaceutical March 25 (Reuters) - Tianjin Development 0882.HK:FY NET PROFIT ATTRIBUTABLE FOR TIANJIN LISHENG PHARMACEUTICAL RMB416.3 MILLIONFY TOTAL OPERATING INCOME FOR TIANJIN LISHENG PHARMACEUTICAL RMB1.39 BILLIONFurther company coverage: 002393.SZ ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622601769","isCrawlerRequest":true}